Tauro-β-muricholic acid sodium structure
|
Common Name | Tauro-β-muricholic acid sodium | ||
---|---|---|---|---|
CAS Number | 145022-92-0 | Molecular Weight | 537.68 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C26H44NNaO7S | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Tauro-β-muricholic acid sodiumTauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC50 of 40 μM[1][2][3]. |
Name | Tauro-β-muricholic acid sodium |
---|
Description | Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC50 of 40 μM[1][2][3]. |
---|---|
Related Catalog | |
Target |
IC50: 40 μM (FXR)[1] |
In Vitro | T-βMCA sodium inhibits FXR reporter activity in the CRC cell line HT29 (EC50 ~10 μM)[3]. T-βMCA sodium dose-dependently increases WNT signaling in HT29 and HCT116 cells[3]. T-βMCA sodium induces proliferation and DNA damage in Lgr5+ cells[3]. |
In Vivo | T-βMCA sodium (400 mg/kg; i.g.; twice a week; for 6 weeks) can effectively recapitulate the ability of HFD to promote CRC progression[3]. T-βMCA sodium treatment also significantly increases levels of serum cytokines, including IFN-γ, IL-6, and IL-17[3]. Animal Model: APCmin/+ mice[3] Dosage: 400 mg/kg Administration: Oral gavage; twice a week; for 6 weeks Result: Markedly decreased intestinal integrity and accelerated tumor growth in the intestine and colon. |
References |
Molecular Formula | C26H44NNaO7S |
---|---|
Molecular Weight | 537.68 |
Storage condition | -20°C |